552a; 44 U.S.C. confirming quantitative results are not standardized to enable comparisons and meta-analyses. Conclusions Lack of standardized SARS-CoV-2 quantitative IgG and neutralization assays precludes assessment of results from published studies. Interassay and interlaboratory validation and standardization ZM 306416 hydrochloride of assays will support attempts to better understand antibody kinetics and longevity of humoral immune reactions postillness, surrogates of immune protection, and vaccine immunogenicity and effectiveness. PublicCprivate partnerships could facilitate realization of these advances in the United States and worldwide. Keywords: immunity, pandemic, quantitative assays, SARS-CoV-2, serology In response to the coronavirus disease 2019 (COVID-19) pandemic, a number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid amplification checks, antigen-based tests, and serologic assays have been developed and used extensively worldwide for diagnostic, screening, and monitoring purposes. Since the start of the pandemic, the US Food and Drug Administration (FDA) offers issued SHCB Emergency Use Authorizations (EUA) for nearly 200 assays to support the COVID-19 response in the United States [1]. The mind-boggling majority of these FDA-authorized assays are nucleic acid amplification tests in the form of real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assays for screening respiratory specimens (nose and nasopharyngeal swabs). Recently, the FDA issued EUAs for quick testing platforms that detect viral antigens. Since April 2020, serologic assays to detect antibodies produced against SARS-CoV-2 have become widely available in the United States. In order to apply SARS-CoV-2 serologic screening strategies to inform public health interventions and individual patient management, serologic correlates of safety against SARS-CoV-2, in terms of antibody type and concentration, and period of immunity conferred must be clearly founded. These results of individual and public health significance ZM 306416 hydrochloride must be determined in association with medical and epidemiologic data on numerous outcomes, such as decreased transmission, decreased period and severity of illness, improved outcomes, prevention of re-infection, and, when available, the effectiveness of vaccine candidates to protect against or decrease severity of main infection. For large understanding and consensus building of correlates of safety, these studies would need to include participants who are demographically diverse in terms of age group, sex, and race/ethnicity, as well as populations disproportionately affected by COVID-19. Historically, for additional bacterial and viral pathogens, such data have been derived from vaccine studies for vaccine-preventable diseases [2, 3], ZM 306416 hydrochloride from studies of natural history of illness for diseases that are not vaccine preventable, and from animal models. As our knowledge of the natural history of SARS-CoV-2 and connected illness is currently growing and ZM 306416 hydrochloride vaccine candidates remain in development, we must ZM 306416 hydrochloride foundation our assessment of serological correlates of safety on peer-reviewed reports of illness and reinfection, convalescent plasma therapy tests, and vaccine candidate studies. There is limited value in lessons learned from the severe acute respiratory syndrome (SARS) outbreak in 2003 [4, 5] and the ongoing outbreak of Middle East Respiratory Computer virus (MERS) [6]; for example, the timing and longevity of immunoglobulin G (IgG) and neutralizing antibodies to these viruses have been variable (ranging from weeks to years), SARS has not re-appeared, MERS infections are of low incidence, and there are currently no vaccines for either of these related coronaviruses. Compared with cellular immune assays, laboratory assays designed to measure humoral immune response based on production of immunoglobulins against SARS-CoV-2.